Truist analyst Asthika Goonewardene lowered the firm’s price target on IGM Biosciences (IGMS) to $2 from $12 and keeps a Hold rating on the shares. The firm is citing the company’s announcement that it is discontinuing both imvotamab and IGM-2644, leaving the company with just the Sanofi (SNY) collaboration as its pipeline, though while this is an unfortunate and disappointing turn of events, Truist believes that it may just be restricted to IGM Biosciences and their platform, the analyst tells investors in a research note.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IGMS:
- Morning Movers: Constellation Energy climbs following deal to buy Calpine
- IGM Biosciences downgraded to Neutral from Buy at Guggenheim
- IGM Biosciences downgraded to Sector Perform from Outperform at RBC Capital
- IGM Biosciences downgraded to Hold from Buy at Stifel
- IGM Biosciences downgraded to Underweight from Equal Weight at Morgan Stanley